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Purpose: To (i) investigate expression of the endothelin-1 (ET-1) gene in peripheral blood mononuclear cells (PBMCs)
of patients with type 2 diabetes mellitus (DM) and (ii) determine what correlations, if any, exist between expression of
ET-1 in patients with type 2 DM and treatment, clinical features, and biochemical markers in diabetic retinopathy (DR).
Methods: The study group included 58 patients with type 2 DM, subdivided into three subgroups: those without DR
(n=19), those with nonproliferative DR (NPDR; n=28), and those with proliferative DR (PDR; n=11). The control group
consisted of 60 individuals. In all groups the mRNA level of ET-1 was estimated using real-time quantitative reverse
transcription PCR.
Results: The mRNA level of ET-1 in patients with NPDR was significantly higher than in those without DR. An increase
in ET-1 expression was observed in patients with PDR as opposed to those without DR. Compared to controls, the mRNA
level of ET-1 was significantly higher both in patients with NPDR and those with PDR. Duration of DM, insulin therapy,
and serum creatinine levels were associated with increased mRNA level of ET-1, whereas medication with sulfonylurea
or angiotensin-converting enzyme inhibitors had the opposite effect.
Conclusions: Expression of ET-1 in PBMCs may be associated with severity of DR in patients with type 2 DM. Long-
standing clinical course of DR; medication with insulin, sulfonylurea, or ACE inhibitors; and serum creatinine levels are
factors possibly associated with changes in ET-1 expression in PBMCs.
Alterations in activity of the endothelin (ET) system are
believed to underlie development of structural and functional
lesions related to type 2 diabetes mellitus (DM). Plasma levels
of endothelins — produced and secreted mostly by epithelial
cells—change  during  the  course  of  type  2  DM.  Such
variations are generally attributed to an increased level of the
endothelin-1 (ET-1) protein, which is associated with severity
of endothelial cell injury [1].
Under normal physiologic conditions, ET-1 is a crucial
protein for the non-neuronal autoregulation of retinal blood
flow. It not only causes constriction and increased tonicity of
blood vessels but also enhances endothelial production of
such  vasodilators  as  nitric  oxide  and  prostacyclines  [2].
Further,  ET-1  is  involved  in  stimulating  proliferation  and
migration of endothelial cells and has potential mitogenic
activity over smooth muscle cells [3].
The relationship between ET-1 plasma concentration and
degree of progression of diabetic retinopathy (DR) has been
demonstrated  in  many  studies  [2,4–8].  In  the  eye,  local
production of ET-1 may result from retinal disease [4]. On the
other hand, the level of ET-1 in the vitreous may result, in part,
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from  damage  to  the  blood–retina  barrier  and  penetrable
vessels. Diabetic microangiopathy occurs not only in ocular
tissues but also in the kidney, nervous system, and skin—
suggesting etiogenic mechanisms not specific to the organ in
question  [9,10].  ET-1  is  produced  by  endothelial  cells,
vascular  smooth  muscle  cells,  macrophages,  leucocytes,
cardiomyocytes,  and  fibroblasts  [10].  Since  leucocytes
produce ET-1, peripheral blood mononuclear cells (PBMCs)
are a potential source of this protein, which may influence the
structural and functional microcirculatory changes observed
in DM. There are, however, no published data regarding the
mRNA level of the ET-1 gene in PBMCs, as measured by real-
time quantitative reverse transcription PCR (qRT–PCR), in
patients with type 2 DM. Furthermore, possible correlations
between the mRNA level of the ET-1 gene in PBMCs and
relevant clinical features or biochemical parameters have not
yet been described.
The goals of this study were to investigate the mRNA
level of ET-1 in PBMCs of patients affected with type 2 DM,
with  or  without  concomitant  DR,  and  examine  possible
correlations between expression of ET-1 within this group of
patients  and  treatment,  clinical  features,  and  biochemical
markers of DR.
METHODS
Patients: Included in this study were 58 patients with type 2
DM treated in the Department of Ophthalmology, Medical
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1272University of Silesia, St. Barbara Hospital. All patients were
informed about the research and signed the informed consent.
The  study  was  approved  by  the  Bioethics  Committee  of
Medical  University  of  Silesia,  Katowice  (decision  NN
6501/146/I/05). Diagnosis of type 2 DM was based on World
Health Organization criteria [11]. The clinical features and
biochemical markers are presented in Table 1. Patients with
type 2 DM were further subdivided into three groups: those
without DR (n=19), comprising six males and 13 females,
mean  age=63.4  years  (range  49–79  years);  those  with
nonproliferative  diabetic  retinopathy  (NPDR;  n=28),
comprising 12 males and 16 females, mean age=58.5 years
(range 42–83 years); and those with proliferative diabetic
retinopathy (PDR; n=11), comprising seven males and four
females, mean age=67 years (range 52–75 years). No patient
with type 2 DM without DR was diagnosed with diabetic
macular edema. The presence of diabetic macular edema was
revealed in patients with DR. The control group consisted of
60 individuals, all with a negative history of DM, normal
fasting  serum  glucose,  and  normal  findings  on
ophthalmoscopic examination (Table 1). Exclusion criteria
were as follows: past or active retinal or optic nerve disorders,
primary open-angle glaucoma, angina pectoris, hypertrophic
cardiomyopathy,  history  of  myocardial  infarction,  stroke,
peripheral  vascular  diseases,  diabetic  nephropathy,
neuropathy, or microalbuminuria as confirmed by a strip test
(Micral Test II, Roche, Germany) of a morning urine sample.
There were no statistically significant differences between the
study groups and the control group with regard to gender, age,
or body mass index. In DM patients, arterial hypertension was
more  frequent  (Fisher’s  exact  test,  p=0.005)  and  glucose
concentrations were higher (Mann–Whitney U test, p<0.001)
than in control group individuals.
RNA extraction from peripheral blood mononuclear cells:
Venous blood samples were collected into EDTA tubes, and
a 7.5-ml sample from each patient was centrifuged on a Ficoll-
Conray gradient (specific gravity 1.077; Immunobiological
Co., Gumma, Japan) immediately after blood collection.
Total  RNA  was  extracted  from  specimens  using  a
commercially available kit (Total RNA Prep Plus kit; A&A
Biotechnology, Gdansk, Poland), based on the Chomczynski
and  Sacchi  method,  and  according  to  manufacturer's
instructions [12]. RNA extracts were treated with DNase I
(MBI  Fermentas,  Vilnius,  Lithuania),  according  to
manufacturer's  instructions.  The  quality  of  extracts  was
checked electrophoretically using 0.8% agarose gel stained
with ethidium bromide. Results were analyzed and recorded
using the gel documentation system 1D Bas-Sys (Biotech-
Fisher,  Perth,  Australia).  Total  RNA  concentration  was
determined  by  spectrophotometric  measurement  at  A260,
A280, and A310 in 5-μl capillary tubes, using the Gene Quant
II  RNA/DNA  Calculator  (Pharmacia  Biotech,  Cambridge,
UK).
Real-time quantitative reverse transcription PCR assay: The
mRNA  level  of  ET-1  and  glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) genes were evaluated on the basis
of mRNA copy number per 1 μg of total RNA, using real-time
qRT–PCR  and  SYBR  Green  I  chemistry  (SYBR  Green
Quantitect RT–PCR kit; QIAGEN, Valencia, CA). Analysis
was performed using an Opticon™ DNA Engine Continuous
Fluorescence  Detector  (MJ  Research,  Watertown,  MA).
qRT–PCR  assays  were  performed  in  triplicate  for  all  81
samples.  GAPDH  was  included  to  monitor  RT–PCR
efficiency for all samples. Oligonucleotide primers specific
for: ET-1 (5′-CCA ATC TTG GAA CAG TCT TTT CCT-3′
forward, 5′-GGA CAT CAT TTG GGT CAA CAC TCC-3′
reverse) and GAPDH (5′-GAA GGT GAA GGT CGG AGT-3′
forward, 5′-GAA GAT GGT GAT GGG ATT C-3′ reverse)
genes were described previously by Berger et al. [13] and
Ercolani et al. [14], respectively.
The thermal profile for one-step RT–PCR was as follows:
50 °C for 30 min for reverse transcription, 95 °C for 15 min,
40 cycles at 94 °C for 45 s, 54 °C for 45 s, and 72 °C for 35
s. The point at which the PCR product is first detected above
a  fixed  threshold—  termed  cycle  threshold  (Ct)—was
determined for each sample, and the average Ct of triplicate
samples  was  calculated.  Each  run  was  completed  using
melting  curve  analysis  to  confirm  specificity  of  the
amplification  and  absence  of  primer  dimers.  RT–PCR
products  were  separated  on  6%  polyacrylamide  gels  and
visualized with silver salts.
To quantify the results obtained by RT–PCR for ET-1 and
GAPDH, the standard curve method was used [15,16]. To
simultaneously  detect  the  expression  profile  of  each
investigated  gene,  commercially  available  standards  of  β-
actin (ACTB) cDNA (TaqMan® DNA Template Reagent kit;
PE Applied Biosystems, Inc., Foster, CA) were used at five
different concentrations (ranging from 400 to 8,000 copies of
ACTB cDNA).
Amplification plots for each dilution of the commercially
available standard template were used to determine Ct values
[15,16]. Correlation coefficients for standard curves ranged
from 0.988 to 0.995, indicating a high degree of confidence
for measurement of the copy number of molecules in each
sample. Copy numbers of analyzed mRNAs were calculated
from the linear regression of the standard curve.
Statistical analyses: Statistical analyses were performed using
Statistica  8.0  software  (StatSoft,  Tulsa,  OK),  with  a
significance  level  set  at  p<0.05.  Values  are  expressed  as
median (Me), minimum and maximum, and lower (25th) and
upper (75th) quartiles. The hypertension prevalence rate was
tested with Fisher's exact test. For statistically testing outlying
values in continuous variables, Dixon’s test was used. For the
relationship between DR and ET-1, the mRNA level was
tested using Kruskal–Wallis and post hoc paired comparisons
based on mean ranks. Differences in individual qualitative
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1273TABLE 1. SELECTED CLINICAL FEATURES AND BIOCHEMICAL MARKERS OF TYPE 2 DIABETUS MELLITUS (DM) PATIENTS AND CONTROLS
Characteristic Type 2 DM (n=58) Controls (n=60)
Gender
M 21 33
F 37 27
Age (year) 60.0 (42.0–83.0) 61.0 (52.0–76.0)
BMI (kg/m2) 29.4 (22.0–44.0) 27.0 (21.0–32.0)
BMI
Normal 9 24
Overweight 23 24
Obese 26 12
Smoking
Yes 6 0
No 52 60
Arterial hypertension
Yes 40 4
No 18 56
*Glycemia 142.5 (69.0–387.0) 100.0 (89.0–108.0)
*Serum creatinine 0.9 (0.5–1.1) 1.2 (0.9–1.1)
*Total cholesterol 193.0 (139.0–326.0) 220.0 (184.0–267.0)
*Triglycerides 158.0 (69.0–343.0) 110.0 (86.0–193.0)
*HDL cholesterol 49.5 (40.0–64.0) 65.0 (47.0–128.0)
*LDL cholesterol 125.5 (100.0–20.0) 147.0 (52.0–199.0)
Glycosylated hemoglobin (%) 7.5 (5.3–9.8) -
Length of clinical course (year) 10.5 (1.0–29.0) -
Type of retinopathy
No DR 19 -
NPDR 28 -
PDR 11 -
Diabetic macular edema
Yes 0 -
No 58 -
Frequency of glycemic control
Less than once daily 14 -
Once daily 14 -
Twice daily 13 -
Thrice daily 17 -
Insulin therapy
Yes 31 -
No 27 -
Length of insulin therapy (years) 7.0 (0–25.0) -
Medication with oral anti-diabetic drugs
Yes 44 -
No 14 -
Type of the anti-diabetic drug
Metformin 36 -
Sulfonylureas 24 -
Alpha-glucosidase inhibitor 6 -
Type of anti-hypertensive drug
β-blocker 13 -
Ca-blocker 11 -
ACE inhibitor 29 -
Diuretics 12 -
Values of clinical and biochemical parameters are expressed as median (minimum–maximum). Abbreviations: M represents
male; F represents female. *Expressed as mg%.
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1274variables and expression of ET-1 between analyzed groups
were tested using the Mann–Whitney U-test. The relationship
between quantitative variables and expression of the ET-1
gene was determined by Spearman’s rank correlation test.
RESULTS
In this study, the mRNA level of the ET-1 gene in PBMCs
from patients with type 2 DM complicated by retinopathy was
determined  using  real-time  qRT–PCR.  Risk  factors,  with
possible influence on mRNA levels of the gene in this group
of patients, were also defined.
In the first stage of the study, specificity of the RT–PCR
assay for the target genes was confirmed experimentally by
PAGE and amplimer melting temperature. For each RT–PCR
product, a single peak was obtained by melting curve analysis
at the expected temperatures: ET-1, 78.8 °C ±0.16; GAPDH,
80.1 °C ±0.22 (data not shown). Gel electrophoresis revealed
the  presence  of  a  single  product  of  the  predicted  length
(ET-1, 269 bp; GAPDH, 226 bp; data not shown).
In the second stage of the study, levels of ET-1 mRNA in
patients  and  controls  were  assessed  (Figure  1).  Among
patients with type 2 DM, the greatest number of ET-1 mRNA
copies/μg  total  RNA  was  found  in  the  PDR  subgroup
(Me=4745.0),  somewhat  fewer  in  the  NPDR  subgroup
(Me=3893.1),  and  the  least  in  DM  patients  without  DR
(Me=487.8). In the control group, there were fewer copies of
ET-1 mRNA/μg total RNA than in patients with type 2 DM
(Me=431.0).  Statistical  analyses  revealed  differences
between analyzed groups (p=0.0008, Kruskal–Wallis=16.81).
The  ET-1  mRNA  level  in  PDR  and  NPDR  patients  was
significantly higher than in diabetic patients without DR (post
hoc paired comparisons based on mean ranks, p=0.007 and
p=0.005, respectively).
No statistically significant difference in the number of
copies of ET-1/μg total RNA was found between NPDR and
PDR patients. The mRNA level of ET-1 was significantly
higher  in  the  NPDR  and  PDR  groups  (post  hoc  paired
comparisons based on mean ranks, p=0.036 and p=0.026,
respectively) compared to controls. No statistically significant
difference in the mRNA level of ET-1 was found between DM
patients without DR and controls.
In  the  third  stage  of  the  study,  correlations  between
expression of ET-1 in patients with type 2 DM and treatment,
clinical  features,  and  biochemical  markers  of  DR  were
investigated  (Table  2  and  Table  3).  Among  all  analyzed
nonparametric variables, only insulin therapy and medication
with sulfonylurea or angiotensin-converting enzyme (ACE)
inhibitors had any influence on expression levels of ET-1.
Patients treated with insulin showed increased expression of
the  gene  (Mann–Whitney  U  test,  p=0.003),  whereas  the
mRNA level was significantly lower in patients receiving
sulfonylurea medication (Mann–Whitney U test, p=0.004) or
ACE inhibitors (Mann–Whitney U test, p=0.029). Parametric
variables associated with changes in the expression of ET-1
included  prolonged  clinical  course  of  DM  and  increased
creatinine  levels  in  venous  blood.  Both  the  long-standing
clinical course of DM (Spearman test, p=0.013, r=0.292) and
increased levels of serum creatinine (Spearman test, p=0.023,
r=0.368) correlated with increased mRNA level of ET-1.
Figure  1.  Comparison  of  number  of
copies of endothelin-1 (ET-1) mRNA in
patients  and  controls.  Statistical
significance  was  found  for  control
versus  nonproliferative  diabetic
retinopathy (NPDR; p=0.036), control
versus proliferative diabetic retinopathy
(PDR;  p=0.026),  diabetes  mellitus
(DM)  without  DR  versus  NPDR
(p=0.005), and DM without DR versus
PDR  (p=0.007).  Boxes  and  whisker
plots  present  medians±quartiles  and
minimum-maximum  values  of  copy
number per 1 μg total RNA.
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1275No  statistically  significant  correlation  between  ET-1
level and age, gender, bodyweight and height, body mass
index,  or  medication  with  metformin,  α-glucosidase
inhibitors,  β  blockers,  calcium  blockers,  or  diuretics  was
found.  There  was  also  no  significant  correlation  between
frequent follow-ups, duration of insulin therapy, and smoking
habit,  and  blood  levels  of  glucose,  triglycerides,  total
cholesterol,  high-density  lipoprotein,  low-density
lipoproteins, or glycosylated hemoglobin.
DISCUSSION
Vascular complications resulting from chronic hyperglycemia
and  insulin  resistance  are  inseparably  associated  with  the
pathogenesis of type 2 DM, leading, in turn, to increased
mortality rates. The destructive influence of hyperglycemia
on eye tissues is manifested in DR. Thus, understanding the
pathogenesis of vascular complications in type 2 DM is key
for  eventually  reducing  these  deleterious  sequelae  [17].
Changes in the activity of the ET system are significant in
initiating the structural and functional damages characteristic
of  the  complications  in  type  2  DM.  In  many  previously
published studies [4–6,17–20], attempts to evaluate the ET-1
concentration in patients with DR as well as the potential
correlation between ET-1 concentration and degree of disease
progression were made. Increases in ET-1 protein levels in the
vitreous were highly correlated with increased concentration
of  ET-1  in  the  blood  serum  of  patients  with  PDR  [4].
Moreover,  an  increase  of  ET-1  in  the  vitreous  body  was
observed, together with an increased level of plasma proteins,
suggesting an influx of ET-1 from the plasma into the eye
[4]. On the other hand, ET-1 may be produced locally by
ocular tissues. However, there is a complete lack of data
regarding the ET-1 gene mRNA level, and thus the source of
this protein in DR is still unclear. PBMCs, as a source of the
ET-1  protein,  may  significantly  influence  the  molecular
TABLE 2. FACTORS ASSOCIATED WITH CHANGES IN ENDOTHELIN (ET)-1 GENE EXPRESSION IN PATIENTS WITH TYPE 2 DIABETUS MELLITUS (DM)
Variable n ET-1 mRNA (copies/mg total RNA)a p
Gender
M 21 2620 (267–4383) NS
F 37 3385 (563–5242)
Smoking
Yes 6 4052 (1382–6035) NS
No 52 2620 (283–4549)
Insulin therapy
Yes 31 3929 (1710–6278) 0.003
No 27 1300 (56–3807)
Anti-diabetic drug
Metformin
Yes 36 3642 (9674–5242) NS
No 22 1930 (125–3913)
Sulfonyloureas
Yes 24 1049 (56–3359) 0.004
No 34 4067 (1464–5912)
Alpha-glucosidase inhibitors
Yes 6 3215 (2020–4022) NS
No 52 2620 (236–4650)
Anti-hypertensive drug
β-blocker
Yes 13 4745 (798–6202) NS
No 45 2575 (259–4341)
Ca-blockers
Yes 11 2575 (138–5034) NS
No 47 3182 (458–4572)
ACE inhibitor
Yes 29 1622 (89–4136) 0.029
No 29 3607 (1244–5109)
Diuretics
Yes 12 2575 (538–3551) NS
No 46 3521 (275–4682)
a Median  with the 25th and 75th centiles–quartiles are presented. Abbreviations: M represents male; F represents female; NS
represents not significant.
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1276changes leading to microangiopathy in DM, independent of
the organ studied, including retina.
Our  observations  suggest  that  increases  in  ET-1
expression in PBMCs are associated with development of
microangiopathy, which complicates the course of type 2 DM.
Given  stimulation  of  proliferation  and  migration  of
endothelial cells by ET-1, a hypothesis may be formulated that
increased  expression  of  ET-1  in  PBMCs  is  involved  in
initiation  of  the  molecular  changes  leading  to
microangiopathy. These observations are in line with those of
other studies investigating the level of plasma ET-1 in venous
blood of patients with type 2 DM complicated by DR [5,6,
17–20]. However, our results were obtained for the whole
population  of  PBMCs.  Thus  we  cannot  indicate  which
particular cellular population is the main source of ET-1.This
information would be very helpful in understanding the basis
of molecular changes leading to diabetic retinopathy.
Our  results  suggest  relationships  between  ET-1
expression and such factors as duration of clinical course of
disease,  insulin  therapy,  medication  with  sulfonylureas  or
ACE  inhibitors,  and  serum  creatinine  levels.  Prolonged
duration of DM results in an increased mRNA level of ET-1,
with subsequent increase of hyperglycemic incidents that lead
to increased activity of kinase C protein [21,22], production
of  insoluble  polymers  (so-called  advanced  glycation
endproducts) [2], and increased synthesis of diacyloglycerol
[21,23–25]. All of the above result in increased generation of
free radicals, which in turn activate proliferative changes and
induce hyperglycemia-related injury to tissues, blood vessels,
and the endothelium.
Another  factor  associated  with  ET-1  expression  in
patients with type 2 DM is insulin therapy. The increase in
expression of ET-1 in patients receiving insulin is consistent
with  results  of  experimental  studies  of  effects  of  insulin
administration  on  ET-1  plasma  levels  under  physiologic
conditions [26]. Both Ferri et al. [27] and Piatti et al. [28]
proved that there is a correlation between plasma levels of
ET-1  and  dosage  (and  timing)  of  insulin  administered  to
euglycemic patients with type 2 DM and hyperinsulinemia.
The relationship between plasma levels of ET-1 and insulin
(both endogenous and exogenous) is suggested by the fact that
plasma levels of ET-1 are higher in patients with type 2 DM
than in those with type 1 DM [19], most likely due to higher
insulin  levels  and  associated  insulin  resistance.  It  is  also
conceivable  that  endogenous  and  exogenous  insulin  may
affect expression of ET-1.
The next factor found to be associated with expression of
ET-1  is  medication  with  the  sulfonylureas.  In  our  study
statistically  significant  difference  in  expression  of  ET-1
between patients treated with sulfonylurea and those that are
not was revealed. The lack of a difference in ET-1 mRNA
levels between patients with DM without DR and the control
population would be caused by therapy with sulfonylureas.
The ET-1 mRNA level may be modulated by this agent, which
suggests the potential protective effect of such therapy in DM.
The potential pharmaceutical modulation of ET-1 release was
previously described by Vingolo et al. [29]. They had shown
that  Defibrotide  had  multi-site  activity,  which  reduced  or
delayed  the  need  for  laser  treatment  in  NPDR  patients.
However,  there  are  no  data  regarding  the  molecular
mechanism by which the sulfonylureas can cause a decrease
in ET-1 expression.
Medication  with  ACE  inhibitors  is  another  factor
associated  with  reduction  in  expression  of  ET-1.  Our
statistical analysis revealed that the level of ET-1 mRNA is
definitely lower in patients treated with ACE inhibitors. This
suggests  that  activation  of  the  rennin–angiotensin–
aldosterone system plays an important role in the pathogenesis
of  both  microangiopathy  and  macroangiopathy  in  DM
patients  [30].  Inhibition  of  the  rennin–angiotensin–
TABLE 3. CORRELATION BETWEEN ENDOTHELIN-1 (ET-1) MRNA LEVELS AND CLINICAL FEATURES/ BIOCHEMICAL MARKERS IN
PATIENTS WITH TYPE 2 DIABETUS MELLITUS (DM)
ET–1 mRNA (copies/μg total RNA) r–value p-value
Age (year) 0.067 NS
BMI (kg/m2) −0.149 NS
Length of clinical course (year) 0.292* 0.02
Length of insulin therapy (year) 0.003 NS
**Glycemia −0.196 NS
**Serum creatinine 0.368* 0.01
**Total cholesterol −0.249 NS
**Triglycerides 0.127 NS
**HDL cholesterol −0.004 NS
**LDL cholesterol −0.447 NS
Glycosylated hemoglobin (%) −0.014 NS
Statistical significance: *p<0.05; ** mg%, NS represents not significant.
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1277aldosterone system may be achieved by administration of
ACE  inhibitors.  These  therapeutic  agents  delay  not  only
development  and  progression  of  vascular  pathology,  e.g.,
nephropathy, but probably also retinopathy in patients with
type 1 or 2 DM.
Serum level of creatinine is yet another factor influencing
expression of ET-1. Statistical analysis of ET-1 expression in
patients with DR complicating type 2 DM revealed a positive
correlation between increased ET-1 mRNA level and serum
levels of creatinine. However, all currently studied patients
had normal serum creatinine levels and had negative albumin
strip test results. This suggests that the ET-1 mRNA level is a
more  sensitive  marker  of  early  epithelial  damage  within
glomeruli, complicating the course of type 2 DM. Results of
animal studies support this hypothesis [31,32].
Our  analyses  suggest  that  the  ET-1  mRNA  level  in
PBMCs is associated with severity of DR in patients with type
2 DM. A long-standing clinical course of DM; medication
with  insulin,  sulfonylurea,  or  ACE  inhibitors;  and  serum
creatinine levels are factors associated with changes in ET-1
expression.  There  is,  however,  a  need  to  study  a  larger
population  to  confirm  the  usefulness  of  quantitative
determination  of  ET-1  mRNA  in  PBMCs  for  monitoring
progression of retinal changes in patients with type 2 DM.
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